Akston Biosciences Corp

S-1/A amended

FWP supplemental

S-1/A amended

FWP supplemental

S-1/A amended

FWP supplemental

S-1/A amended

Akston Biosciences Corp. is conducting an IPO to raise capital for its development of biopharmaceutical products targeting companion animals. The company's Ambifect® platform aims to improve monoclonal antibody therapies for conditions like cancer and arthritis in pets. The IPO offers 2,222,222 shares at an estimated price range of $8.00-$10.00, with plans to list on the NYSE American under 'AXTN'. The offering includes underwriting discounts, warrants, and a 45-day option for additional shares.

S-1/A amended

Akston Biosciences Corp, a pet biotechnology company, is conducting an initial public offering (IPO) of 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share. The company focuses on developing biopharmaceutical products for companion animals, leveraging its proprietary Ambifect® platform to create innovative therapies for conditions like cancer, dermatitis, and arthritis. The IPO aims to fund clinical trials and commercialization efforts, with the company expecting to list on the NYSE American under the symbol "AXTN." Akston is an emerging growth company and smaller reporting company, electing reduced reporting requirements under U.S. securities laws.

S-1 filed

Akston Biosciences Corp, a pet biotechnology company, is conducting an IPO to raise capital for its biopharmaceutical product pipeline targeting companion animals. The company plans to offer 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share, aiming to list on the NYSE American under the symbol "AXTN." The offering is underwritten by ThinkEquity. Akston's lead product candidate, AKS-701d, targets PD-L1 for canine bladder cancer, with potential approvals anticipated in 2027 and 2029 for additional candidates. The company emphasizes its proprietary Ambifect® platform to reduce dosing frequency and costs for monoclonal antibody therapies.

DRS/A amended

Akston Biosciences Corp. filed an amended registration statement (DRS/A) for its initial public offering (IPO), detailing a firm commitment offering of common stock. The company, focused on developing biopharmaceutical products for companion animals, utilizes its proprietary Ambifect® platform to address unmet medical needs in pets. The IPO aims to list on NYSE American under the symbol 'AXTN,' with an estimated share price range and underwriting details provided. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market competition.

DRS filed

Akston Biosciences Corp, a pet biotechnology company, is conducting a confidential IPO filing (DRS) for its common stock. The company focuses on developing biopharmaceutical products for companion animals, leveraging its proprietary Ambifect® platform to address serious conditions like cancer and chronic pain. The offering includes a lead candidate, AKS-701d, targeting PD-L1 for canine bladder cancer, with potential regulatory approval anticipated in 2025. The IPO is underwritten by ThinkEquity, with the company seeking to list on a stock exchange under the symbol "AXTN." Akston is an emerging growth company with risks tied to regulatory approvals, competition, and financial constraints.